Intron-targeted mirna therapy for repeat expansion disorders
This innovative therapy targets retained intron sequences in repeat-expanded transcripts using miRNAs, aiming for allele-specific knockdown in disorders like myotonic dystrophy type 2. The approach promises increased specificity and stability, advancing therapeutic developments.
Overview
Intron-targeted miRNA therapy offers a novel approach for treating repeat expansion disorders such as myotonic dystrophy type 2 (DM2). This method focuses on targeting retained intron sequences within repeat-expanded transcripts, utilizing microRNAs (miRNAs) to achieve allele-specific knockdown. By honing in on these retained introns, the therapy aims to selectively reduce the toxic RNA associated with the disease without affecting the healthy allele, which is crucial for maintaining normal cellular function.
Technical specifications
Key features:
- Utilizes miRNAs designed to target retained intron sequences in DM2 and similar disorders
- Focus on allele-specific knockdown, distinguishing toxic repeat-expanded transcripts from healthy ones
- Increased stability and export of retained introns enhance targeting efficacy
- Screening of CNBP intron 1-targeting miRNAs for potency and specificity in DM2 patient-derived myotubes
The miRNAs are developed and tested for their ability to preferentially target repeat-expanded alleles. This involves creating control miRNAs targeting the coding sequence and assessing allelic knockdown through targeted amplicon sequencing.
Technology readiness level
This therapy is currently at Technology Readiness Level 2, indicating that the concept has been formulated and basic research has been conducted. Future work will involve validation in cultured cells and patient-derived myotubes, with a focus on demonstrating potency and specificity under controlled experimental conditions.
About Virginia Commonwealth University
Virginia Commonwealth University is a comprehensive public research university and academic health center in Richmond, combining broad disciplinary breadth with a downtown, two‑campus footprint and top‑tier (R1) research activity. Integration with VCU Health enables large‑scale clinical research and translation, while shared core research facilities support collaborative, industry‑oriented R&D. Its urban location places faculty and students adjacent to the VA Bio+Tech Park and within a growing Mid‑Atlantic innovation corridor, and an optional engineering co‑op program creates a reliable talent pipeline for partners. Research is backed by competitive federal funding, including NIH and NSF. VCU TechTransfer and Ventures manages IP, licensing and startup formation.
delivered to your inbox.